Compare BANR & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANR | NKTR |
|---|---|---|
| Founded | 1890 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2015 | 1996 |
| Metric | BANR | NKTR |
|---|---|---|
| Price | $70.29 | $70.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $70.00 | ★ $146.67 |
| AVG Volume (30 Days) | 424.7K | ★ 1.1M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | ★ 15.57 | N/A |
| EPS | ★ 1.60 | N/A |
| Revenue | N/A | ★ $307,711,000.00 |
| Revenue This Year | $0.73 | N/A |
| Revenue Next Year | $5.69 | N/A |
| P/E Ratio | $43.03 | ★ N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $57.05 | $21.02 |
| 52 Week High | $72.65 | $109.00 |
| Indicator | BANR | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 57.62 | 54.99 |
| Support Level | $62.97 | $64.30 |
| Resistance Level | $72.65 | $76.78 |
| Average True Range (ATR) | 1.57 | 3.47 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 60.71 | 47.61 |
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho, and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.